<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1383" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="812" end="816"/><type9:PFSMean xmi:id="4" sofa="1" begin="961" end="971"/><type9:OSMean xmi:id="5" sofa="1" begin="1009" end="1019"/><type9:OSTime xmi:id="8" sofa="1" begin="674" end="680"/><type9:OSTime xmi:id="6" sofa="1" begin="1046" end="1052"/><type9:OSRate xmi:id="7" sofa="1" begin="1078" end="1083"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given&#13;&#10;on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in&#13;&#10;advanced non-small cell lung cancer (NSCLC).&#13;&#10;METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD)&#13;&#10;schedule in an open-label, multicentre phase II study in patients with previously&#13;&#10;treated, advanced NSCLC. Patients &gt; or =18 years with stage IIIB/IV NSCLC after&#13;&#10;failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The&#13;&#10;primary end point was objective response rate (ORR). Secondary end points&#13;&#10;included progression-free survival (PFS), overall survival (OS), 1-year survival &#13;&#10;rate, and safety.&#13;&#10;RESULTS: Of 47 patients receiving sunitinib, one patient achieved a confirmed&#13;&#10;partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11&#13;&#10;(23.4%) had stable disease (SD) &gt; or =8 weeks. Five patients had SD&gt;6 months.&#13;&#10;Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI&#13;&#10;31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5).&#13;&#10;Treatment was generally well tolerated.&#13;&#10;CONCLUSIONS: The safety profile and time-to-event analyses, albeit relatively low&#13;&#10;response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a&#13;&#10;potential therapeutic agent for patients with advanced, refractory NSCLC."/><cas:View sofa="1" members="2 3 4 5 8 6 7"/></xmi:XMI>